Business Wire

BDA

Share
BDA to Spotlight Bermuda Market at RIMS Virtual Conference

The Bermuda Business Development Agency (BDA) will host a virtual panel discussion on Bermuda’s liability market and a Bermuda networking break as part of RIMS, the risk management society® annual conference, a comprehensive risk management event that connects and informs the risk management community. The BDA is proud to be a diamond sponsor of this year’s event, RIMS LIVE, which takes place from April 19–30.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406006077/en/

The panel, titled “Changes and Trends in Liability Risk,” will be held on April 22 from 2–3 p.m. ADT. The session will feature Judy Gonsalves, division president at Chubb Bermuda; Saadia Savory, vice president and head of casualty Bermuda at Aspen Insurance; and Kirsten Beasley, interim head, Willis Towers Watson Bermuda. Moderated by Jasmine DeSilva, the BDA’s business development manager for risk and insurance solutions, the panel will explore the current state of the liability market, emerging trends, and the Bermuda market’s response.

“RIMS is the largest risk event of the year — it is a staple in the calendar and the Bermuda market has proudly attended for more than 35 years,” BDA’s CEO Roland Andy Burrows said. “The BDA and Bermuda are extensively committed to supporting and growing the risk management industry here, and participating in the RIMS annual conference is a key part of that. Bermuda continues to work hard to remain at the forefront of commercial trends and drives innovation forward as one of the world’s most important insurance and reinsurance hubs.”

For those who want to connect with Bermuda and the BDA, or find out more, the BDA will host a virtual booth where delegates can learn more about the market, view videos, and engage in live chat. Delegates can also schedule video meetings.

On a lighter note, the BDA will be bringing Bermuda to the attendees during the “Take a Break in Bermuda” networking event on April 20 at 4:30 p.m. ADT, providing an opportunity to hear from the Premier of Bermuda, the Hon. E. David Burt, JP, MP; Bermuda’s Minister of Finance, the Hon. Curtis Dickinson, JP, MP; and BDA CEO Roland Andy Burrows, who will all be speaking from the beautiful Hamilton Princess & Beach Club.

Also from the Hamilton Princess, Jasmine DeSilva and Andrew Holmes, Bermuda brand director for Goslings, will make Bermuda’s famous Rum Swizzle cocktail in Sheila Gosling’s Maytag vintage washing machine from 1964 — the same appliance Bermuda’s late social queen used to prepare drinks in the 1960s. The BDA will also announce the winner of an all-expenses paid trip to Bermuda, including a stay at the Hamilton Princess.

For more information on RIMS and to register for the conference, click here . To schedule a meeting with a BDA team member, please email jasmine@bda.bm or olivia@bda.bm . For more information on the BDA, click here .

CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye